Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices

AAPS Journal

Volumn 19, Issue 3, 2017, Pages 865-874

  Melin, Johanna ^a,b,c   Prothon, Susanne ^c   Kloft, Charlotte ^a   Cleton, Adriaan ^d   Amilon, Carl ^c   Jorup, Carin ^e   Bäckman, Per ^f   Olsson, Bo ^c,g   Hamrén, Ulrika Wählby ^c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Graduate Research Training program PharMetrX   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

^d BAYER PHARMA AG   (Germany)

^e ASTRAZENECA   (United Kingdom)

^f Global Respiratory Group   (United Kingdom)

^g Emmace Consulting AB   (Sweden)

Author keywords

glucocorticoid receptor; inhalation; pharmacokinetics

Indexed keywords

HORMONE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; [2,2,2 TRIFLUORO N [1 [1 (4 FLUOROPHENYL)INDAZOL 5 YL]OXY 1 (3 METHOXYPHENYL)PROPAN 2 YL]ACETAMIDE]; 2,2,2-TRIFLUORO-N-(1-((1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)OXY)-1-(3-METHOXYPHENYL)-2-PROPANYL)ACETAMIDE; ACETAMIDE DERIVATIVE; ANTIASTHMATIC AGENT; INDAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRY POWDER INHALER; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ACETAMIDES; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DRY POWDER INHALERS; HUMANS; INDAZOLES; MALE; YOUNG ADULT;

EID: 85014683283     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-0042-8     Document Type: Article

References (21)

1. Gauvreau AGM, Boulet L, Leigh R, Donald W, Killian KJ, Davis BE, et al. A non-steroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015;191:161–7. doi:10.1164/rccm.201404-0623OC.
2. Hansson T, Berger M, Dahmen J, Edman K, Eriksson A, Gabos B, et al. Discovery of AZD5423, a potent and selective non-steroidal glucocorticoid receptor modulator for the inhaled treatment of respiratory diseases. Presentation presented at 245th National Meeting of the American Chemical Society, New Orleans, LA; 2013. Abstract MEDI-278.
3. Werkström V, Prothon S, Ekholm E, Jorup C, Edsbäcker S. Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD5423, following inhalation in healthy volunteers. Basic Clin Pharmacol Toxicol. 2016;119:574–81. doi:10.1111/bcpt.12621.
4. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Ekelund K, Gustavsson L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, editors. Controlled pulmonary drug delivery. New York: Springer New York; 2011. p. 21–50.
5. Olsson B, Borgström L, Lundbäck H, Svensson M. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Deliv. 2013;26:355–69. doi:10.1089/jamp.2012.0986.
6. Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2013;26:138–44. doi:10.1089/jamp.2012.0975.
7. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52:37–42. doi:10.1007/s40262-012-0021-x.
8. Borghardt JM, Weber B, Staab A, Kunz C, Formella S, Kloft C. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br J Clin Pharmacol. 2016;81:538–52. doi:10.1111/bcp.12780.
9. Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76:868–79. doi:10.1111/bcp.12118.
10. Parra-Guillen ZP, Weber B, Sharma A, Freijer J, Retlich S, Borghardt JM, et al. Population pharmacokinetic analysis of tiotropium in healthy volunteers after intravenous administration and inhalation. J Pharmacokinet Pharmacodyn. 2014;41 Suppl 1:S54. doi:10.1007/s10928-014-9379-8.
11. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80:372–80. doi:10.1111/bcp.12637.
12. Global Strategy for Asthma Management and Prevention, Global initiative for asthma (GINA). GINA Report. 2009. http://www.ginasthma.com
13. Bäckman P, Tehler U, Olsson BL. Predicting exposure after oral inhalation of the Selective Glucocorticoid Receptor Modulator AZD5423 based on dose, deposition pattern and mechanistic modeling of pulmonary disposition. J Aerosol Med Pulm Drug Deliv. 2016. doi:10.1089/jamp.2016.1306.
14. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79:241–57. doi:10.1016/j.cmpb.2005.04.005.
15. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2016. http://www.r-project.org/
16. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on pirana, PsN, and xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50. doi:10.1038/psp.2013.24.
17. Beal SL. Ways to Fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504. doi:10.1023/A:1012299115260.
18. Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21:247–58. doi:10.1016/j.pupt.2007.08.005.
19. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–99. doi:10.1046/j.1365-2125.2003.01892.x.
20. ICRP. Human respiratory tract model for radiological protection. ICRP publication 66. Ann ICRP. 1994; 24.
21. Forbes B, Bäckman P, Christopher D, Dolovich M, Li BV, Morgan B. In vitro testing for orally inhaled products: developments in science-based regulatory approaches. Am Assoc Pharm Sci J. 2015;17:837–52. doi:10.1208/s12248-015-9763-3.